State of Alaska Department of Revenue Sells 342 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

State of Alaska Department of Revenue lowered its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,325 shares of the company’s stock after selling 342 shares during the quarter. State of Alaska Department of Revenue’s holdings in Amphastar Pharmaceuticals were worth $791,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Sanctuary Advisors LLC bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at $388,000. GAMMA Investing LLC boosted its position in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after buying an additional 273 shares during the period. nVerses Capital LLC grew its holdings in shares of Amphastar Pharmaceuticals by 18.2% during the third quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock worth $126,000 after buying an additional 400 shares in the last quarter. Raymond James & Associates raised its position in Amphastar Pharmaceuticals by 1.7% in the 3rd quarter. Raymond James & Associates now owns 116,677 shares of the company’s stock valued at $5,662,000 after buying an additional 1,958 shares during the last quarter. Finally, Retirement Guys Formula LLC acquired a new position in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $203,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $31.02 on Friday. The company has a fifty day moving average price of $36.87 and a two-hundred day moving average price of $43.33. Amphastar Pharmaceuticals, Inc. has a one year low of $30.95 and a one year high of $56.38. The stock has a market cap of $1.49 billion, a P/E ratio of 10.34, a P/E/G ratio of 2.07 and a beta of 0.81. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AMPH. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $66.00 to $36.00 in a research report on Tuesday, February 4th. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus target price of $50.33.

Insider Activity at Amphastar Pharmaceuticals

In other news, EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares in the company, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.